Gufic BioSciences Q2 Results 2026: PAT ₹23 Cr (+39.5% YoY)
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹288Cr
- +21.6% YoY
- +10.5% QoQ
- Net profit
- ₹23Cr
- +39.5% YoY
- +5.2% QoQ
- Margin
- 16.8%
- +0.8 pp YoY
- −1.1 pp QoQ
Guidance rank: #43 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on Gufic BioSciences Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2 FY27 Revenue: Rs. 288.4 crore, up from Rs. 230.4 crore in Q2 FY26, representing a ~25% year-on-year increase. Q2 FY27 EBITDA: Rs. 49.7 crore, up from Rs. 37.9 crore in Q2 FY26 (YoY increase of Rs. 11.8 crore).
From Gufic BioSciences Ltd's Q2 FY27 earnings-call transcript · updated 14 Nov 2026.
How did Gufic BioSciences' revenue grow in the September 2026 quarter?
- Q2 FY27 Revenue: Rs. 288.4 crore, up from Rs. 230.4 crore in Q2 FY26, representing a ~25% year-on-year increase.
- H1 FY27 Revenue: Rs. 550.8 crore.
- Q2 FY27 EBITDA Margin: 17.23%, improved from 16.45% in Q2 FY26.
- Profit After Tax for Q2 FY27: Rs. 23.5 crore vs Rs. 14.9 crore in Q2 FY26, showing significant YoY growth.
- The presentation mentions the Indore manufacturing platform US FDA inspection success, indicating readiness for regulated markets and scale-up plans.
- It highlights the ramp-up at Indore shifting incremental growth and volumes from Navsari (Q1 & Q2 FY26 to FY27).
2 more points from Gufic BioSciences Ltd's call on revenue
Create a free account to keep reading this call
What happened to Gufic BioSciences' margins in Q2 FY27?
Q2 FY27 EBITDA: Rs. 49.7 crore, up from Rs. 37.9 crore in Q2 FY26 (YoY increase of Rs. 11.8 crore).
Locked: what Gufic BioSciences Ltd said on margins
Also locked on this page: fundraising, order book
Free account, 30 seconds. No card needed.
What capex is Gufic BioSciences planning?
- Indore facility: advanced lyophilized injectable manufacturing platform with installed capacity of 50 mn lyophilized vials, 30 mn liquid vials, 72 mn ampoules per year; commercial production started Oct 2024.
- Phased approach milestones for Indore plant:
- IQ/OQ completed Oct 2023
- PQ completed Dec 2023–Jun 2024
- Media fills completed by Oct 2024
- 203 State FDA product approvals received (ongoing)
- 40 product tech transfers completed; 27 in progress
- 30% capacity utilization target FY26 (on track)
- EU GMP audit done; certification pending FY27
- US FDA pre-approval inspection done with three observations being addressed FY27
- CMO contracts commenced; vendor audits ongoing
2 more points from Gufic BioSciences Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Gufic BioSciences raising money or cutting debt?
See what Gufic BioSciences Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Gufic BioSciences' order book?
See what Gufic BioSciences Ltd said on order book & pipeline — free account, 30 seconds.
Gufic BioSciences Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the table below.
Gufic BioSciences Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| Revenue | 288 | 237 | +21.6% | 261 | +10.5% |
| Operating profit (EBITDA) | 48 | 38 | +28.1% | 47 | +4% |
| Operating margin | 16.8% | 16% | +0.8 pp | 17.9% | -1.1 pp |
| Profit before tax | 31 | 23 | +39.2% | 30 | +4.7% |
| Net profit (PAT) | 23 | 17 | +39.5% | 22 | +5.2% |
| EPS (₹) | 2.34 | 1.68 | +39.3% | 2.22 | +5.4% |
Source: Gufic BioSciences Ltd's results filing to NSE (consolidated), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹261 Cr, net profit ₹22 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →More Q2 FY27 results in Pharmaceuticals & Biotechnology
- Sun Pharmaceutical Industries Q2 FY27 results
- Divis Laboratories Q2 FY27 resultsCapex ₹1,638 Cr
- Torrent Pharmaceuticals Q2 FY27 results
- Laurus Labs Q2 FY27 results
- Zydus Lifesciences Q2 FY27 results
- Dr Reddy's Labs Q2 FY27 resultsCapex ₹186 Cr
- Cipla Q2 FY27 results
- Mankind Pharma Q2 FY27 results
All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings
Continue your research
What Gufic BioScience's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Nectar Lifescience (Q2 FY27)
Quarterly EBITDA**: ₹52.7 crore, down 88% YoY . Key results statement takeaways from Nectar Lifescience Ltd's Q2 FY27 results statement — and how it ranks again
- KRM Ayurveda (Q2 FY27)
Q2 FY27 Total Income:** ₹3,529.95 Lakhs, a 48.08% year-on-year (YoY) increase from Q2 FY26 (₹2,383.80 Lakhs). Key investor presentation takeaways from KRM Ayurv
- Dishman Carbogen (Q2 FY27)
For the quarter ended September 30, 2026, the consolidated total income from operations (net) was ₹507.37 crores, compared to ₹652.65 crores in the same…
- Natural Capsules (Q2 FY27)
11.67% increase. Key results statement takeaways from Natural Capsules Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Gufic BioSciences Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Gufic BioSciences Ltd Q2 FY27 results?
Q2 FY27 Revenue: Rs. 288.4 crore, up from Rs. 230.4 crore in Q2 FY26, representing a ~25% year-on-year increase. Q2 FY27 EBITDA: Rs. 49.7 crore, up from Rs. 37.9 crore in Q2 FY26 (YoY increase of Rs. 11.8 crore).
What is Gufic BioSciences Ltd share price analysis?
Gufic BioSciences Ltd currently shows a neutral. The stock trades at a P/E of 64.6 with a market cap of ₹4,753 Cr. Investors should review the full earnings analysis for detailed insights.
Is Gufic BioSciences Ltd planning capital expenditure?
Indore facility: advanced lyophilized injectable manufacturing platform with installed capacity of 50 mn lyophilized vials, 30 mn liquid vials, 72 mn ampoules per year; commercial production started O.
Keep Gufic BioSciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.